- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07950878
Capturing Quality of Life and Priorities for Clinical Research in Parents and Patients With Autosomal Recessive Polycystic Kidney Disease (ARPKD PROM)
Chronic kidney disease (CKD) in childhood is a significant burden and reduces the quality of life for both children and their parents. CKD is especially burdensome when it progresses to end stage kidney disease (ESKD, previously referred to as end-stage renal disease or ESRD), placing considerable demands on a childs entire family. Although studies are available for all-cause CKD and for some disease subsets, there is no study capturing quality of life in children or adolescents specifically affected by autosomal recessive polycystic kidney disease (ARPKD). These children are often severely affected prenatally and postnatally have problems due to massive kidney enlargement, hypertension, kidney failure, and portal hypertension. They often need to receive kidney replacement therapy during childhood.
The need to include patients and their lived experience in the design of clinical trials exists for all diseases, but is implemented infrequently, especially in the field of rare diseases. The negative consequences of limited patient/parent input in clinical trial design for rare diseases has been recently highlighted by a report from the International Rare Diseases Research Consortium (IRDiRC).
Studieoversikt
Detaljert beskrivelse
The first primary objective of this study is to assess the quality of life of children affected by autosomal recessive polycystic kidney disease (ARPKD) and their parents, using validated survey instruments.
The second primary objective is to determine priorities of patients, caregivers, and healthcare professionals regarding outcome measures in order to determine a set of core outcomes for future ARPKD-related clinical trials The secondary aim is to validate the use of existing quality of life questionnaire for this cohort of children with ARPKD and to compare their hrQoL to previously published cohorts of children with all-cause chronic kidney disease.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Jasmine Jaber
- Telefonnummer: 267-425-5325
- E-post: jaberj2@chop.edu
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19146
- Rekruttering
- Children's Hospital of Philadelphia
-
Ta kontakt med:
- Jasmine Jaber
- Telefonnummer: 267-425-5325
- E-post: jaberj2@chop.edu
-
Hovedetterforsker:
- Lisa Guay-Woodford, M.D.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Subjects should be between 0-25 years of age and have an ICD-10 diagnosis code for ARPKD in the CHOP Epic EHR.
Beskrivelse
Inclusion Criteria:
- Subjects should be over 18 years of age and permanently live in the same household as the child/ young person with ARPKD.
Exclusion Criteria:
- Insufficient understanding of the questions due to intellectual capabilities or language barriers. However, translation by a professional interpreter is permissible.
Lack of written informed consent. Subjects that choose not to have their responses recorded.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: FAMILY_BASED
- Tidsperspektiver: OTHER
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Patients with ARPKD and their caregivers
|
Families will be asked to fill out a series of questionnaires |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PedsQL ESRD Questionnaire
Tidsramme: 5 years
|
PedsQL ESRD Module (quality of life in children with end-stage renal disease) validated questionnaire on health-related QOL for children ≥ 24 months and adults < 25 years with renal disease. 35 questions. Ranking scale (not at all, sometimes, a lot). Items are reverse-scored and linearly transformed to a 0 to 100 scale, where higher scores indicate a better quality of life. |
5 years
|
|
SDQ (strength and difficulties questionnaire)
Tidsramme: 5 years
|
validated brief emotional and behavioral screening tool. 38 questions. Ranking scale (not true, somewhat true, certainly true). Items divided into five scales of five items each, scored from 0 to 10 per scale, with four problem scales summed into a Total Difficulties score from 0 to 40. Higher scores indicate greater difficulty. |
5 years
|
|
IFS (impact on family scale)
Tidsramme: 5 years
|
Caregiver burden will be captured by recording the burden on family life with the "Impact on Family Scale"(IFS). 35 questions. Ranking scale (strongly agree, agree, disagree, strongly disagree). Scored by rating each item on a 4-point Likert scale and summing the items to get a total score, where higher scores indicate a greater perceived impact of a child's health condition or disability on the family. |
5 years
|
|
ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children)
Tidsramme: 5 years
|
Caregiver burden will be captured by recording the burden on family life with ULQIE (Ulm Quality of Life Inventory for Parents of Chronically Ill Children). 29 questions. Ranking scale (never, rarely, sometimes, often, always). 5-point rating scale (0 = "never" to 4 = "always") based on the past 7 days, where higher scores indicate better parental quality of life. |
5 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Lisa Guay-Woodford, M.D., CHOP
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Ciliopatier
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Nyresykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Genetiske sykdommer, medfødte
- Medfødte abnormiteter
- Abnormiteter, flere
- Nyresykdommer, cystisk
- Polycystiske nyresykdommer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Polycystisk nyre, autosomal recessiv
- Helsevesenets kvalitet, tilgang og evaluering
- Undersøkelsesteknikker
- Epidemiologiske metoder
- Datainnsamling
- Helsevesenets evalueringsmekanismer
- Kvalitet på helsehjelpen
- Folkehelse
- Miljø og folkehelse
- Undersøkelser og spørreskjemaer
Andre studie-ID-numre
- 24-022381
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .